The estimated Net Worth of Stacy Ann Coen is at least $2.93 Milhão dollars as of 2 February 2024. Ms Coen owns over 14,350 units of Immunogen stock worth over $2,432,253 and over the last 4 years she sold IMGN stock worth over $111,719. In addition, she makes $388,972 as Sr. VP & Chief Bus. Officer at Immunogen.
Ms has made over 7 trades of the Immunogen stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 14,350 units of IMGN stock worth $448,294 on 2 February 2024.
The largest trade she's ever made was exercising 108,609 units of Immunogen stock on 15 November 2023 worth over $762,435. On average, Ms trades about 20,421 units every 10 days since 2020. As of 2 February 2024 she still owns at least 77,857 units of Immunogen stock.
You can see the complete history of Ms Coen stock trades at the bottom of the page.
Stacy A. Coen is the Sr. VP & Chief Bus. Officer at Immunogen.
As the Sr. VP & Chief Bus. Officer of Immunogen, the total compensation of Ms Coen at Immunogen is $388,972. There are 6 executives at Immunogen getting paid more, with Mark Enyedy having the highest compensation of $3,917,560.
Ms Coen is 50, she's been the Sr. VP & Chief Bus. Officer of Immunogen since . There are 13 older and 3 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
Stacy's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., eMark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: